Status:

ACTIVE_NOT_RECRUITING

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Lead Sponsor:

Candel Therapeutics, Inc.

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAt...

Eligibility Criteria

Inclusion

  • Inclusion Criteria include:
  • Localized prostate cancer meeting the NCCN criteria of Intermediate Risk or patients having only one NCCN high-risk feature
  • NCCN Intermediate Risk is defined as having at least one of the following: PSA 10-20 ng/ml, Gleason score =7, T2b-T2c
  • High Risk with a single high risk feature is defined as having only one of the following: PSA\>20 ng/ml, Gleason score 8-10, or T3a
  • Excluded are those in the following risk groups: Low risk; High risk with more than 1 high risk factor; Locally advanced/very high risk=T3b-T4; Metastatic: N1 or M1
  • Planning to undergo standard prostate-only external beam radiation therapy
  • ECOG Performance Status 0-2
  • Exclusion Criteria include:
  • Liver disease, including known cirrhosis or active hepatitis
  • Patients on systemic corticosteroids (\>10mg prednisone per day) or other immunosuppressive drugs
  • Known HIV+ patients
  • Regional lymph node involvement or distant metastases
  • Patients planning to receive whole pelvic irradiation
  • Prior treatment for prostate cancer, except TURP or ADT. For ADT, it may only be given for a maximum of 6 months
  • Patients who had or plan to have orchiectomy as the form of hormonal ablation
  • Known sensitivity or allergic reactions to acyclovir or valacyclovir

Exclusion

    Key Trial Info

    Start Date :

    September 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2030

    Estimated Enrollment :

    711 Patients enrolled

    Trial Details

    Trial ID

    NCT01436968

    Start Date

    September 1 2011

    End Date

    December 1 2030

    Last Update

    July 30 2025

    Active Locations (73)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 19 (73 locations)

    1

    Arizona Center for Cancer Care - Gilbert

    Gilbert, Arizona, United States, 85297

    2

    Arizona Urology Specialists

    Glendale, Arizona, United States, 85308

    3

    Arizona Oncology Services Foundation

    Multiple Locations, Arizona, United States, 85260

    4

    Arizona Center for Cancer Care - Peoria

    Peoria, Arizona, United States, 85381